Cataya Bio has snagged $34.5 million in a Series B financing round, Zenosic has bagged $41.4 million in Series A1 financing, while Grit Biotechnology has secured $55.2 million in Series B funding.
Eight Roads Ventures co-leads Cataya Bio’s Series B round
Synthetic biology firm Cataya Bio has snagged 250 million yuan ($34.5 million) in a Series B financing round co-led by Eight Roads Ventures.
The funding has brought the firm’s total fundraising to 500 million yuan ($93.3 million), according to a company release. Previously, the firm wrapped up its Series A+ round in November 2022 led by Eight Roads Ventures and HongShan, previously known as Sequoia Capital China.
Founded in September 2021, the Shanghai-headquartered firm engages in the biomanufacturing of chemical and biochemical products, with operations in Japan and the US.
Sincere Capital co-leads Zenosic’s Series A1 round
Chinese chip maker Zenosic has bagged 300 million yuan ($41.4 million) in a Series A1 financing round led by Sincere Capital and GP Capital.
The round saw the participation of several local investors, including Ningmeng Investment, Yiling Capital, and Zhongbo Capital, among others, according to a company announcement. The Nanjing-headquartered firm will use the proceeds to accelerate product R&D.
Founded in 2021, Zenosic engages in the design and R&D of high-performance network chips. It counts Shunwei Capital, Gaorong Capital, and Innoangel Fund among its backers.
CICC Capital leads Grit Biotechnology’s Series B round
Grit Biotechnology, a clinical-stage cell therapy company specialising in the field of tumour immunotherapy, has secured 400 million yuan ($55.2 million) in a Series B financing round led by CICC Capital.
Qianhai Ark Asset Management, Matrix Partners China, Sherpa Healthcare Partners, Liando U Valley, Yuanhe Capital, and Decheng Capital are among the investors who joined the round, according to the company release.
Founded in 2019, the Zhuhai-headquartered firm previously sealed its Series A extended financing round in July 2021 led by GL Ventures.